Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 27

1.

Role of the Renin-Angiotensin-Aldosterone System beyond Blood Pressure Regulation: Molecular and Cellular Mechanisms Involved in End-Organ Damage during Arterial Hypertension.

Muñoz-Durango N, Fuentes CA, Castillo AE, González-Gómez LM, Vecchiola A, Fardella CE, Kalergis AM.

Int J Mol Sci. 2016 Jun 23;17(7). pii: E797. doi: 10.3390/ijms17070797. Review.

2.

Modulation of Immunity and Inflammation by the Mineralocorticoid Receptor and Aldosterone.

Muñoz-Durango N, Vecchiola A, Gonzalez-Gomez LM, Simon F, Riedel CA, Fardella CE, Kalergis AM.

Biomed Res Int. 2015;2015:652738. doi: 10.1155/2015/652738. Epub 2015 Sep 10. Review.

3.

Cost-Effectiveness of Therapeutic Drug Monitoring in Diagnosing Primary Aldosteronism in Patients With Resistant Hypertension.

Velasco A, Chung O, Raza F, Pandey A, Brinker S, Arbique D, Price A, Lotan Y, Das SR, Vongpatanasin W.

J Clin Hypertens (Greenwich). 2015 Sep;17(9):713-9. doi: 10.1111/jch.12570. Epub 2015 Apr 27.

4.

Somatic mutations of the ATP1A1 gene and aldosterone-producing adenomas.

Gomez-Sanchez CE, Kuppusamy M, Gomez-Sanchez EP.

Mol Cell Endocrinol. 2015 Jun 15;408:213-9. doi: 10.1016/j.mce.2014.12.004. Epub 2014 Dec 10. Review.

5.

Interfering with mineralocorticoid receptor activation: the past, present, and future.

Dorrance AM.

F1000Prime Rep. 2014 Aug 1;6:61. doi: 10.12703/P6-61. eCollection 2014. Review.

6.

NP-59 SPECT/CT imaging in stage 1 hypertensive and atypical primary aldosteronism: a 5-year retrospective analysis of clinicolaboratory and imaging features.

Chen YC, Chiu JS, Wang YF.

ScientificWorldJournal. 2013 Oct 21;2013:317934. doi: 10.1155/2013/317934. eCollection 2013.

7.

Efficacy of adrenal venous sampling is increased by point of care cortisol analysis.

Viste K, Grytaas MA, Jørstad MD, Jøssang DE, Høyden EN, Fotland SS, Jensen DK, Løvås K, Thordarson H, Almås B, Mellgren G.

Endocr Connect. 2013 Nov 15;2(4):236-42. doi: 10.1530/EC-13-0063. Print 2013.

8.

Interaction between nitric oxide and superoxide in the macula densa in aldosterone-induced alterations of tubuloglomerular feedback.

Zhang Q, Lin L, Lu Y, Liu H, Duan Y, Zhu X, Zou C, Manning RD Jr, Liu R.

Am J Physiol Renal Physiol. 2013 Feb 1;304(3):F326-32. doi: 10.1152/ajprenal.00501.2012. Epub 2012 Dec 5.

9.

Predictors of successful outcome after adrenalectomy for primary aldosteronism.

Wang W, Hu W, Zhang X, Wang B, Bin C, Huang H.

Int Surg. 2012 Apr-Jun;97(2):104-11. doi: 10.9738/CC140.1.

10.

Evolution features of hypertensive patients with primary aldosteronism--prospective study.

Chioncel V, Păun D, Amuzescu B, Sinescu C.

J Med Life. 2012 Sep 15;5(3):354-9. Epub 2012 Sep 25.

11.

Unilateral adrenal hyperplasia is a usual cause of primary hyperaldosteronism. Results from a Swedish screening study.

Sigurjonsdottir HA, Gronowitz M, Andersson O, Eggertsen R, Herlitz H, Sakinis A, Wangberg B, Johannsson G.

BMC Endocr Disord. 2012 Sep 8;12:17. doi: 10.1186/1472-6823-12-17.

12.

A novel point mutation in the KCNJ5 gene causing primary hyperaldosteronism and early-onset autosomal dominant hypertension.

Charmandari E, Sertedaki A, Kino T, Merakou C, Hoffman DA, Hatch MM, Hurt DE, Lin L, Xekouki P, Stratakis CA, Chrousos GP.

J Clin Endocrinol Metab. 2012 Aug;97(8):E1532-9. doi: 10.1210/jc.2012-1334. Epub 2012 May 24.

13.

Active renin mass concentration to determine aldosterone-to-renin ratio in screening for primary aldosteronism.

Corbin F, Douville P, Lebel M.

Int J Nephrol Renovasc Dis. 2011;4:115-20. doi: 10.2147/IJNRD.S22245. Epub 2011 Jul 28.

14.

Changes in the perceived epidemiology of primary hyperaldosteronism.

Fagugli RM, Taglioni C.

Int J Hypertens. 2011;2011:162804. doi: 10.4061/2011/162804. Epub 2011 Aug 4.

15.

Common secondary causes of resistant hypertension and rational for treatment.

Faselis C, Doumas M, Papademetriou V.

Int J Hypertens. 2011 Mar 2;2011:236239. doi: 10.4061/2011/236239.

16.

Primary aldosteronism: A Japanese perspective.

Satoh F, Morimoto R, Iwakura Y, Ono Y, Kudo M, Takase K, Ito S.

Rev Endocr Metab Disord. 2011 Mar;12(1):11-4. doi: 10.1007/s11154-011-9161-9. Review.

17.

Resistant hypertension workup and approach to treatment.

Makris A, Seferou M, Papadopoulos DP.

Int J Hypertens. 2010 Dec 26;2011:598694. doi: 10.4061/2011/598694.

18.

The molecular biology, biochemistry, and physiology of human steroidogenesis and its disorders.

Miller WL, Auchus RJ.

Endocr Rev. 2011 Feb;32(1):81-151. doi: 10.1210/er.2010-0013. Epub 2010 Nov 4. Review. Erratum in: Endocr Rev. 2011 Aug;32(4):579.

19.

Genetic analyses of the chimeric CYP11B1/CYP11B2 gene in a Korean family with glucocorticoid-remediable aldosteronism.

Lee IS, Kim SY, Jang HW, Kim MK, Lee JH, Lee YH, Jo YS.

J Korean Med Sci. 2010 Sep;25(9):1379-83. doi: 10.3346/jkms.2010.25.9.1379. Epub 2010 Aug 14.

20.

Laboratory investigation of primary aldosteronism.

Stowasser M, Taylor PJ, Pimenta E, Ahmed AH, Gordon RD.

Clin Biochem Rev. 2010 May;31(2):39-56.

Items per page

Supplemental Content

Write to the Help Desk